NCT04521998

Brief Summary

The aim of this pilot study is to compare the effectiveness of electroacupuncture or transcutaneous electrical nerve stimulation in reducing the tenderness in the patients with rheumatoid arthritis. The study adopted a pragmatic, randomized, patient-centered approach to investigate the effectiveness of clinical symptoms and quality of life.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 4, 2020

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

August 16, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 21, 2020

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2025

Completed
Last Updated

July 20, 2022

Status Verified

July 1, 2022

Enrollment Period

5.2 years

First QC Date

August 16, 2020

Last Update Submit

July 18, 2022

Conditions

Keywords

Comparative effectiveness researchelectroacupuncturetranscutaneous electrical nerve stimulationrheumatoid arthritis:randomized clinical trial

Outcome Measures

Primary Outcomes (1)

  • Morning stiffness(scoring range 0~10 and lasting time : min/day)

    Changes from baseline to end of intervention and 4 weeks after intervention completed

    baseline, week 5, and week 9

Secondary Outcomes (6)

  • Simplified disease activity index (scoring range 0.0 ~ 86.0)

    baseline, week 5, and week 9

  • Disease Activity Score 28 (scoring range 0.0 ~ 9.4)

    baseline, week 5, and week 9

  • Erythrocyte sedimentation rate

    baseline, week 5, and week 9

  • Clinical Disease Activity Index (scoring range 0.0 ~ 76.0)

    baseline, week 5, and week 9

  • Pain Visual Analogue Scale (scoring range 0 ~ 10)

    baseline, week 5, and week 9

  • +1 more secondary outcomes

Study Arms (2)

electroacupuncture

EXPERIMENTAL

The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.

Device: electroacupuncture

Transcutaneous electrical nerve stimulation

EXPERIMENTAL

The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.

Device: TENS

Interventions

Electroacupuncture used to reduce the inflammation was proved previously.

electroacupuncture
TENSDEVICE

Patients who unlike needles would like to choose TENS as treatment for pain relief.

Transcutaneous electrical nerve stimulation

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old
  • Met the American College of Rheumatology criteria (2010) for RA
  • Classification of X-ray : Stage I\~III
  • The participants' RA medication regimen (DMARD, NSAID, steroid)were eligible if they were on a stable dose for at least 3 months before entry into and throughout the study.
  • All patients were instructed not to make any changes in their background therapies during the study.
  • Intra-articular or pulse steroid were not permitted during the study

You may not qualify if:

  • Be treated with biological agents, such as antagonist of TNF-alpha, IL-6, Jak, and CD20 mono antibody in the last 3 months
  • Having history of serious drug allergy
  • Pregnancy or breastfeeding
  • Bleeding or coagulation disorders
  • Localized skin infections
  • Uncontrolled or ill-controlled blood pressure with diastolic pressure≥110 mmHg
  • Any other acupuncture treatment or herbal medication for RA within 2 weeks before screening
  • needle phobia
  • Intra-articular corticosteroid or pulse steroid within 4 weeks preceding the study
  • Any severe chronic or uncontrolled comorbid disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University Hospital

Taichung, 404, Taiwan

RECRUITING

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

ElectroacupunctureTranscutaneous Electric Nerve Stimulation

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeuticsAcupuncture TherapyComplementary TherapiesElectric Stimulation TherapyPhysical Therapy ModalitiesRehabilitationAnalgesiaAnesthesia and AnalgesiaAnesthesia

Study Officials

  • Hung-Rong Yen, M.D. Ph.D.

    China Medical University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hung-Rong Yen, M.D. Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 16, 2020

First Posted

August 21, 2020

Study Start

August 4, 2020

Primary Completion

September 30, 2025

Study Completion

September 30, 2025

Last Updated

July 20, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations